Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.
Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.
We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.
In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months. Request Insights
The Metastatic Breast Cancer Treatment Market is estimated to grow with a high CAGR during the forecast period, i.e., 2021-2029. The increasing prevalence of breast cancer globally, along with the growing recurrence rate of breast cancer is expected to fuel the development of this market. The growth of the market can also be attributed to factors such as the increasing geriatric population and an increase in exposure to cancer risk factors linked to social and economic development. Cancer is currently the second leading cause of death worldwide. According to the Globocan report, global cancer burden is estimated to have risen to 19.3 million cases and 10 million cancer-related deaths in 2020. According to Globocan report 2020, the incidence rate of breast cancer was 5.20% which accounted for 2.26 million new cases globally with a mortality rate of 6.9%. Such increasing prevalence of breast cancer is expected to drive the growth of global metastatic breast cancer treatment market.
The market is segmented based on treatment type into chemotherapy, radiation therapy, biologic, targeted therapy, breast surgery, and hormone therapy, out of which, chemotherapy and radiation therapy segment is anticipated to grab the largest share by the end of 2021 on account of its high level of specificity and lesser side-effects. Moreover, increasing government approval of new treatment & drugs globally is also projected to contribute to the growth of the segment during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
Based on end-user, the hospital segment held the largest share in the global metastatic breast cancer treatment market on the back of increasing patient influx and increasing spending by the hospitals on breast cancer treatments.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing breast cancer prevalence and the rising geriatric population in the region. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing healthcare investment, accompanied by the presence of leading healthcare service providers, and the increasing prevalence of cancer in the region. Along with this, the countries in North America such as the United States is promoting campaigns for breast cancer patients, which is also expected to contribute to the market growth in the region. According to the report published by the National Cancer Institute, in 2020, 1.8 million new cancer cases were registered in the United States. Such increasing rate of cancer is further expected to drive the demand for metastatic breast cancer treatment in the North American countries. Alternatively, the market in Europe is also anticipated to occupy a significant share in the global metastatic breast cancer treatment market on account of its proven success in terms of technology development and a high prevalence of breast cancer in the region. As per the analysis of the Globocan, 0.53 million new breast cancer cases were registered in the European Union, with 0.14 million deaths in 2020. Such growing number of deaths due to breast cancer is expected to increase the R&D activities to develop better treatment in the market.
The global metastatic breast cancer treatment market is further classified on the basis of region as follows:
Market Segmentation
Our in-depth analysis of the global metastatic breast cancer treatment market include the following segments:
By Treatment Type
By End-user
Growth Drivers
Challenges
Top Featured Companies Dominating the Market
FREQUENTLY ASKED QUESTIONS
Rising prevalence of breast cancer and increasing investments in R&D are the key factors driving market growth.
The market is anticipated to attain a high CAGR over the forecast period, i.e., 2021-2029.
Lack of awareness and high risk associated with the radiation exposure are estimated to hamper market growth.
The market in Asia Pacific region will provide ample growth opportunities owing to rising geriatric population and increasing breast cancer prevalence.
The major players dominating the Metastatic Breast Cancer Treatment market are F. Hoffmann-La Roche Ltd, Merck & Company, Inc., AstraZeneca Plc., Novartis, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Johnson & Johnson, GlaxoSmithKline plc., and others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by treatment type, end-user and region.
With respect to treatment type, the chemotherapy & radiation therapy segment is anticipated to hold the largest market share owing to the growing requirement for metastatic breast cancer treatment.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2020 Research Nester. All Rights Reserved
